CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The IMMUNISA project focuses on developing a therapeutic vaccine, ISA101b, for treating cervical cancer caused by human papillomavirus. The project aims to conduct a clinical trial to assess the vaccine's efficacy in combination with chemotherapy, targeting improved patient outcomes.
Cervical cancer (CxCa) is caused by high risk types of the human papillomavirus (a.o. HPV16).
Prophylactic HPV vaccination is not the standard of care in all European countries, and where approved it is not sufficiently adopted.
Once infected, these vaccines no longer prevent premalignant lesions and CxCa, which can only be treated with surgery or radio-chemotherapy.
However, this is not effective in recurrent/advanced CxCa.
In underdeveloped countries, CxCa is often detected when it is too late…
KATHOLIEKE UNIVERSITEIT LEUVEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
GRANZER REGULATORY CONSULTING & SERVICES
Germany
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Netherlands, Leiden
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Netherlands, Rijswijk
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
